Advertisement
Canada markets closed

  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CAD/USD

    0.7320
    +0.0019 (+0.26%)
     

  • CRUDE OIL

    83.31
    +1.41 (+1.72%)
     

  • Bitcoin CAD

    90,770.52
    -80.18 (-0.09%)
     

  • CMC Crypto 200

    1,431.45
    +16.69 (+1.18%)
     

  • GOLD FUTURES

    2,337.40
    -9.00 (-0.38%)
     

  • RUSSELL 2000

    2,002.71
    +35.23 (+1.79%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • NASDAQ

    15,696.64
    +245.33 (+1.59%)
     

  • VOLATILITY

    15.85
    -1.09 (-6.43%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • CAD/EUR

    0.6837
    -0.0013 (-0.19%)
     
MARKETS LIVE BLOG:

S&P 500, NASDAQ NOTCH BIG WINS WITH TESLA EARNINGS ON DECK

Tech-focused investors prepare for fresh wave of earnings highlighted by struggling Tesla

Needham Sticks to Their Buy Rating for Akcea Therapeutics Inc

Investing.com
·1 min read


Needham analyst Chad Messer reiterated a Buy rating on Akcea Therapeutics (NASDAQ:AKCA) Inc on Wednesday, setting a price target of $41, which is approximately 154.34% above the present share price of 16.12.

Messer expects Akcea Therapeutics Inc to post earnings per share (EPS) of 0.866838 for the second quarter of 2020.

The current consensus among 1 TipRanks analysts is for a Hold rating of shares in Akcea Therapeutics, with an average price target of .
The analysts price targets range from a high of to a low of .

In its latest earnings report, released on 12/31/2019, the company reported a quarterly revenue of 277.48 million and a net profit of 83.16 million. The company's market cap is 1.67 billion.

ADVERTISEMENT

According to TipRanks.com, Needham analyst Chad Messer is a 5-star analyst with an average return of 9.3% and a 46.8% success rate.

Akcea Therapeutics, Inc. engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA.